155 related articles for article (PubMed ID: 36347423)
1. Cathepsin D: Analysis of its potential role as an amyloid beta degrading protease.
Gallwitz L; Schmidt L; Marques ARA; Tholey A; Cassidy L; Ulku I; Multhaup G; Di Spiezio A; Saftig P
Neurobiol Dis; 2022 Dec; 175():105919. PubMed ID: 36347423
[TBL] [Abstract][Full Text] [Related]
2. Recombinant pro-CTSD (cathepsin D) enhances SNCA/α-Synuclein degradation in α-Synucleinopathy models.
Prieto Huarcaya S; Drobny A; Marques ARA; Di Spiezio A; Dobert JP; Balta D; Werner C; Rizo T; Gallwitz L; Bub S; Stojkovska I; Belur NR; Fogh J; Mazzulli JR; Xiang W; Fulzele A; Dejung M; Sauer M; Winner B; Rose-John S; Arnold P; Saftig P; Zunke F
Autophagy; 2022 May; 18(5):1127-1151. PubMed ID: 35287553
[TBL] [Abstract][Full Text] [Related]
3. Enzyme replacement therapy with recombinant pro-CTSD (cathepsin D) corrects defective proteolysis and autophagy in neuronal ceroid lipofuscinosis.
Marques ARA; Di Spiezio A; Thießen N; Schmidt L; Grötzinger J; Lüllmann-Rauch R; Damme M; Storck SE; Pietrzik CU; Fogh J; Bär J; Mikhaylova M; Glatzel M; Bassal M; Bartsch U; Saftig P
Autophagy; 2020 May; 16(5):811-825. PubMed ID: 31282275
[TBL] [Abstract][Full Text] [Related]
4. Haplodeficiency of Cathepsin D does not affect cerebral amyloidosis and autophagy in APP/PS1 transgenic mice.
Cheng S; Wani WY; Hottman DA; Jeong A; Cao D; LeBlanc KJ; Saftig P; Zhang J; Li L
J Neurochem; 2017 Jul; 142(2):297-304. PubMed ID: 28429406
[TBL] [Abstract][Full Text] [Related]
5. Genetic associations between cathepsin D exon 2 C-->T polymorphism and Alzheimer's disease, and pathological correlations with genotype.
Davidson Y; Gibbons L; Pritchard A; Hardicre J; Wren J; Tian J; Shi J; Stopford C; Julien C; Thompson J; Payton A; Thaker U; Hayes AJ; Iwatsubo T; Pickering-Brown SM; Pendleton N; Horan MA; Burns A; Purandare N; Lendon CL; Neary D; Snowden JS; Mann DM
J Neurol Neurosurg Psychiatry; 2006 Apr; 77(4):515-7. PubMed ID: 16543533
[TBL] [Abstract][Full Text] [Related]
6. Neuronal-Targeted TFEB Accelerates Lysosomal Degradation of APP, Reducing Aβ Generation and Amyloid Plaque Pathogenesis.
Xiao Q; Yan P; Ma X; Liu H; Perez R; Zhu A; Gonzales E; Tripoli DL; Czerniewski L; Ballabio A; Cirrito JR; Diwan A; Lee JM
J Neurosci; 2015 Sep; 35(35):12137-51. PubMed ID: 26338325
[TBL] [Abstract][Full Text] [Related]
7. Analysis of cathepsin B and cathepsin L treatment to clear toxic lysosomal protein aggregates in neuronal ceroid lipofuscinosis.
Di Spiezio A; Marques ARA; Schmidt L; Thießen N; Gallwitz L; Fogh J; Bartsch U; Saftig P
Biochim Biophys Acta Mol Basis Dis; 2021 Oct; 1867(10):166205. PubMed ID: 34214607
[TBL] [Abstract][Full Text] [Related]
8. Presynaptic dystrophic neurites surrounding amyloid plaques are sites of microtubule disruption, BACE1 elevation, and increased Aβ generation in Alzheimer's disease.
Sadleir KR; Kandalepas PC; Buggia-Prévot V; Nicholson DA; Thinakaran G; Vassar R
Acta Neuropathol; 2016 Aug; 132(2):235-256. PubMed ID: 26993139
[TBL] [Abstract][Full Text] [Related]
9. Protective effects of positive lysosomal modulation in Alzheimer's disease transgenic mouse models.
Butler D; Hwang J; Estick C; Nishiyama A; Kumar SS; Baveghems C; Young-Oxendine HB; Wisniewski ML; Charalambides A; Bahr BA
PLoS One; 2011; 6(6):e20501. PubMed ID: 21695208
[TBL] [Abstract][Full Text] [Related]
10. Cathepsin D Variants Associated With Neurodegenerative Diseases Show Dysregulated Functionality and Modified α-Synuclein Degradation Properties.
Bunk J; Prieto Huarcaya S; Drobny A; Dobert JP; Walther L; Rose-John S; Arnold P; Zunke F
Front Cell Dev Biol; 2021; 9():581805. PubMed ID: 33681191
[TBL] [Abstract][Full Text] [Related]
11. Butyrylcholinesterase-knockout reduces fibrillar β-amyloid and conserves
DeBay DR; Reid GA; Macdonald IR; Mawko G; Burrell S; Martin E; Bowen CV; Darvesh S
Brain Res; 2017 Sep; 1671():102-110. PubMed ID: 28729192
[TBL] [Abstract][Full Text] [Related]
12. Non-canonical soluble amyloid-beta aggregates and plaque buffering: controversies and future directions for target discovery in Alzheimer's disease.
Brody DL; Jiang H; Wildburger N; Esparza TJ
Alzheimers Res Ther; 2017 Aug; 9(1):62. PubMed ID: 28818091
[TBL] [Abstract][Full Text] [Related]
13. Pharmacogenetic features of cathepsin B inhibitors that improve memory deficit and reduce beta-amyloid related to Alzheimer's disease.
Hook V; Hook G; Kindy M
Biol Chem; 2010 Aug; 391(8):861-72. PubMed ID: 20536395
[TBL] [Abstract][Full Text] [Related]
14. Reduction of the expression of the late-onset Alzheimer's disease (AD) risk-factor
Andrew RJ; De Rossi P; Nguyen P; Kowalski HR; Recupero AJ; Guerbette T; Krause SV; Rice RC; Laury-Kleintop L; Wagner SL; Thinakaran G
J Biol Chem; 2019 Mar; 294(12):4477-4487. PubMed ID: 30692199
[TBL] [Abstract][Full Text] [Related]
15. Brain pyroglutamate amyloid-β is produced by cathepsin B and is reduced by the cysteine protease inhibitor E64d, representing a potential Alzheimer's disease therapeutic.
Hook G; Yu J; Toneff T; Kindy M; Hook V
J Alzheimers Dis; 2014; 41(1):129-49. PubMed ID: 24595198
[TBL] [Abstract][Full Text] [Related]
16. Dispersible amyloid β-protein oligomers, protofibrils, and fibrils represent diffusible but not soluble aggregates: their role in neurodegeneration in amyloid precursor protein (APP) transgenic mice.
Rijal Upadhaya A; Capetillo-Zarate E; Kosterin I; Abramowski D; Kumar S; Yamaguchi H; Walter J; Fändrich M; Staufenbiel M; Thal DR
Neurobiol Aging; 2012 Nov; 33(11):2641-60. PubMed ID: 22305478
[TBL] [Abstract][Full Text] [Related]
17. Genetic inhibition of phosphorylation of the translation initiation factor eIF2α does not block Aβ-dependent elevation of BACE1 and APP levels or reduce amyloid pathology in a mouse model of Alzheimer's disease.
Sadleir KR; Eimer WA; Kaufman RJ; Osten P; Vassar R
PLoS One; 2014; 9(7):e101643. PubMed ID: 24992504
[TBL] [Abstract][Full Text] [Related]
18. Nardilysin prevents amyloid plaque formation by enhancing α-secretase activity in an Alzheimer's disease mouse model.
Ohno M; Hiraoka Y; Lichtenthaler SF; Nishi K; Saijo S; Matsuoka T; Tomimoto H; Araki W; Takahashi R; Kita T; Kimura T; Nishi E
Neurobiol Aging; 2014 Jan; 35(1):213-22. PubMed ID: 23954170
[TBL] [Abstract][Full Text] [Related]
19. APP transgenic modeling of Alzheimer's disease: mechanisms of neurodegeneration and aberrant neurogenesis.
Crews L; Rockenstein E; Masliah E
Brain Struct Funct; 2010 Mar; 214(2-3):111-26. PubMed ID: 20091183
[TBL] [Abstract][Full Text] [Related]
20. Decreased expression of cathepsin D in monocytes is related to the defective degradation of amyloid-β in Alzheimer's disease.
Tian L; Zhang K; Tian ZY; Wang T; Shang DS; Li B; Liu DX; Fang WG; Wang ZY; Chen YH
J Alzheimers Dis; 2014; 42(2):511-20. PubMed ID: 24898658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
